Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

646 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Multi-cohort and longitudinal Bayesian clustering study of stage and subtype in Alzheimer's disease.
Poulakis K, Pereira JB, Muehlboeck JS, Wahlund LO, Smedby Ö, Volpe G, Masters CL, Ames D, Niimi Y, Iwatsubo T, Ferreira D, Westman E; Japanese Alzheimer’s Disease Neuroimaging Initiative; Australian Imaging, Biomarkers and Lifestyle study. Poulakis K, et al. Among authors: ames d. Nat Commun. 2022 Aug 5;13(1):4566. doi: 10.1038/s41467-022-32202-6. Nat Commun. 2022. PMID: 35931678 Free PMC article.
Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial.
Ritchie CW, Bush AI, Mackinnon A, Macfarlane S, Mastwyk M, MacGregor L, Kiers L, Cherny R, Li QX, Tammer A, Carrington D, Mavros C, Volitakis I, Xilinas M, Ames D, Davis S, Beyreuther K, Tanzi RE, Masters CL. Ritchie CW, et al. Among authors: ames d. Arch Neurol. 2003 Dec;60(12):1685-91. doi: 10.1001/archneur.60.12.1685. Arch Neurol. 2003. PMID: 14676042 Clinical Trial.
Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial.
Lannfelt L, Blennow K, Zetterberg H, Batsman S, Ames D, Harrison J, Masters CL, Targum S, Bush AI, Murdoch R, Wilson J, Ritchie CW; PBT2-201-EURO study group. Lannfelt L, et al. Among authors: ames d. Lancet Neurol. 2008 Sep;7(9):779-86. doi: 10.1016/S1474-4422(08)70167-4. Epub 2008 Jul 30. Lancet Neurol. 2008. PMID: 18672400 Clinical Trial.
Appearance modeling of 11C PiB PET images: characterizing amyloid deposition in Alzheimer's disease, mild cognitive impairment and healthy aging.
Fripp J, Bourgeat P, Acosta O, Raniga P, Modat M, Pike KE, Jones G, O'Keefe G, Masters CL, Ames D, Ellis KA, Maruff P, Currie J, Villemagne VL, Rowe CC, Salvado O, Ourselin S. Fripp J, et al. Among authors: ames d. Neuroimage. 2008 Nov 15;43(3):430-9. doi: 10.1016/j.neuroimage.2008.07.053. Epub 2008 Aug 12. Neuroimage. 2008. PMID: 18789389
Effects of anticholinergic drugs on cognitive function in older Australians: results from the AIBL study.
Sittironnarit G, Ames D, Bush AI, Faux N, Flicker L, Foster J, Hilmer S, Lautenschlager NT, Maruff P, Masters CL, Martins RN, Rowe C, Szoeke C, Ellis KA; AIBL research group. Sittironnarit G, et al. Among authors: ames d. Dement Geriatr Cogn Disord. 2011;31(3):173-8. doi: 10.1159/000325171. Epub 2011 Mar 9. Dement Geriatr Cogn Disord. 2011. PMID: 21389718
Advances in structural and molecular neuroimaging in Alzheimer's disease.
Ellis KA, Rowe CC, Szoeke CE, Villemagne VL, Ames D, Chételat G, Martins RN, Masters CL, Fripp J, Acosta O, Raniga P, Bourgeat PT, Salvado O. Ellis KA, et al. Among authors: ames d. Med J Aust. 2011 Feb 21;194(4):S20-3. doi: 10.5694/j.1326-5377.2011.tb02938.x. Med J Aust. 2011. PMID: 21401483
Predictors of rapid cognitive decline in Alzheimer's disease: results from the Australian imaging, biomarkers and lifestyle (AIBL) study of ageing.
Sona A, Zhang P, Ames D, Bush AI, Lautenschlager NT, Martins RN, Masters CL, Rowe CC, Szoeke C, Taddei K, Ellis KA; AIBL Research Group. Sona A, et al. Among authors: ames d. Int Psychogeriatr. 2012 Feb;24(2):197-204. doi: 10.1017/S1041610211001335. Epub 2011 Jul 13. Int Psychogeriatr. 2012. PMID: 21749739 Free article.
Homocysteine, vitamin B12, and folic acid levels in Alzheimer's disease, mild cognitive impairment, and healthy elderly: baseline characteristics in subjects of the Australian Imaging Biomarker Lifestyle study.
Faux NG, Ellis KA, Porter L, Fowler CJ, Laws SM, Martins RN, Pertile KK, Rembach A, Rowe CC, Rumble RL, Szoeke C, Taddei K, Taddei T, Trounson BO, Villemagne VL, Ward V, Ames D, Masters CL, Bush AI. Faux NG, et al. Among authors: ames d. J Alzheimers Dis. 2011;27(4):909-22. doi: 10.3233/JAD-2011-110752. J Alzheimers Dis. 2011. PMID: 21891867
Cortical surface mapping using topology correction, partial flattening and 3D shape context-based non-rigid registration for use in quantifying atrophy in Alzheimer's disease.
Acosta O, Fripp J, Doré V, Bourgeat P, Favreau JM, Chételat G, Rueda A, Villemagne VL, Szoeke C, Ames D, Ellis KA, Martins RN, Masters CL, Rowe CC, Bonner E, Gris F, Xiao D, Raniga P, Barra V, Salvado O. Acosta O, et al. Among authors: ames d. J Neurosci Methods. 2012 Mar 30;205(1):96-109. doi: 10.1016/j.jneumeth.2011.12.011. Epub 2011 Dec 29. J Neurosci Methods. 2012. PMID: 22226742 Free article.
646 results